Paxlovid, Molnupiravir Access Threatened By ‘Dismal' Pharmacy Dispensing Fees, CMS Told

Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.

Oral Antivirals Dispensing Is Time Consuming and Complicated, Pharmacy Group Says • Source: Alamy

COVID-19 oral antivirals from Pfizer Inc. and Merck & Co., Inc. may face access restrictions because health plans and pharmacy benefit managers are providing dispensing fees that many pharmacies believe are inadequate to cover costs.

Pfizer’s Paxlovid (nirmatrelvir/ritonavir) and Merck’s molnupiravir were approved under US Food and Drug Administration emergency use authorizations in late December...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Government Payers

More from Market Access